Emergency departments fall short on delivering timely treatment for sickle cell pain
Reports and Proceedings
Updates every hour. Last Updated: 6-Jun-2026 08:15 ET (6-Jun-2026 12:15 GMT/UTC)
A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications within the first hour as recommended by the American Society of Hematology (ASH) and National Heart, Lung, and Blood Institute (NHLBI).
The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.